Group 1 - BlackRock invested over $1.2 billion in ETH, significantly outpacing its $267 million investment in BTC, indicating a shift in Wall Street's capital direction from Bitcoin as "digital gold" to Ethereum as "digital oil" [1] - The rapid growth of BlackRock's Ethereum ETF (ETHA) from $5 billion to over $10 billion in just 10 days reflects changing investor sentiment towards Ethereum [1] Group 2 - Huajian Medical announced its transformation into the first enhanced Ethereum treasury company in Hong Kong, marking a strategic advancement in the market [2] - The company initiated a global enhanced Ethereum treasury strategy with a multi-layered "downside protection" mechanism and active "yield enhancement" strategies [3] Group 3 - Huajian Medical partnered with HashKey Group to establish a compliant trading channel for large-scale ETH transactions and to explore the integration of crypto assets with real-world assets (RWA) [6] - The company approved the purchase of 5,190 ETH at an average price of HKD 28,798.21, totaling HKD 149 million, as a significant step in its treasury strategy [7] Group 4 - Wall Street's consensus indicates that Ethereum is becoming a necessary asset for institutional investment, supported by five core value pillars including its deflationary nature and yield generation capabilities [8][9] - Ethereum's role as a foundational settlement asset in the DeFi ecosystem positions it as a preferred choice for RWA tokenization and stablecoin issuance [9] Group 5 - Huajian Medical's Ethereum treasury strategy is closely linked to its core business of medical RWA tokenization, aiming to create a unique ecosystem for innovative drug assets [10] - The company's ivd.xyz exchange is designed to facilitate the issuance and trading of medical RWA, integrating Ethereum as a core asset for governance and liquidity [10] Group 6 - The treasury strategy includes an "insurance mechanism" to mitigate volatility risks and a systematic investment approach to smooth costs [13][14] - Huajian Medical aims to address the challenges in innovative drug development financing through its tokenization strategy, enhancing investment efficiency [15] Group 7 - The market is recognizing the potential for Huajian Medical's treasury model to achieve significant valuation, drawing parallels to MicroStrategy's success with Bitcoin [17] - The company's stock price surged by 118% in July and 38.43% on August 6, indicating strong market interest and potential for value discovery [19] Group 8 - Huajian Medical's strategic vision includes applying for stablecoin licenses in both Hong Kong and the U.S., aiming to connect innovative drug assets with global capital through the Ethereum ecosystem [24] - The company's ambition is to leverage Ethereum's properties to create a new benchmark in the Hong Kong market, facilitating the global circulation of Chinese biomedical assets [24]

Group 1 - The core strategy of the company is to launch a "Global Enhanced Ethereum Vault" with a downward protection mechanism, positioning Ethereum (ETH) as a strategic reserve asset [2][5] - The company has entered into a strategic partnership with HashKey Group, which will provide support for large-scale ETH transactions and explore the integration of crypto assets with real-world assets (RWA) [5][10] - The company has invested 149 million HKD to purchase 5,190 ETH and plans to continue increasing its holdings through a dollar-cost averaging strategy, with an approved budget of 880 million HKD [5][10] Group 2 - The "Active Coin Generation" feature is a key highlight of the company's Ethereum Vault strategy, allowing for the tokenization of innovative drug intellectual property (RWA) and trading on the ivd.xyz exchange [8][9] - The ivd.xyz exchange is the first Web3 exchange focused on medical innovation drug RWA, combining centralized and decentralized exchange features to support cross-chain trading [8][9] - The company's downward protection mechanisms include an ATM mechanism, a priority structure, RWA price buyback commitments, and a clinical VC safety net, providing comprehensive protection for investors [9] Group 3 - The Ethereum Vault strategy opens up a potential market capitalization growth space of over 100 billion HKD, drawing parallels with MicroStrategy's Bitcoin strategy, which saw an 80-fold increase in market value [10] - The company’s current market capitalization exceeds 13 billion HKD, indicating significant growth potential compared to MicroStrategy and Metaplanet [10] - The strategy aligns with the Hong Kong Monetary Authority's Ensemble project and China's innovation drug export strategy, aiming to lower financing costs and accelerate technology transfer [11]

Group 1 - The core strategy of the company is to launch a "Global Enhanced Ethereum Vault" with a downward protection mechanism, designating Ethereum (ETH) as a strategic reserve asset [2][6] - The company has entered into a strategic partnership with HashKey Group, which will provide support for large-scale ETH transactions, cost optimization, and liquidity in global markets [6][9] - The company has invested 149 million HKD to purchase 5,190 ETH and plans to continue increasing its holdings through a dollar-cost averaging strategy, with an approved budget of 880 million HKD [6][11] Group 2 - The "Active Coin Generation" feature is a key highlight of the company's Ethereum Vault strategy, allowing for the tokenization of innovative drug intellectual property (RWA) and trading on the ivd.xyz exchange [9][10] - The downward protection mechanism includes various strategies such as ATM mechanisms, priority structures, and price buyback commitments to ensure investor safety [10][11] - The company aims to replicate the success of MicroStrategy and Metaplanet by leveraging its Ethereum holdings to achieve significant market capitalization growth, with a target to exceed 100 billion HKD in two years [11][13] Group 3 - The company's Web3 exchange ecosystem and Ethereum Vault strategy create a new paradigm for financing, circulation, and revenue distribution in innovative drug development [13] - This approach aligns with the Hong Kong Monetary Authority's policy for efficient cross-border asset circulation and supports China's strategy for innovative drug commercialization [13] - The company aims to provide a compliant and transparent Web3 entry point for retail investors and patients, accelerating the availability of critical medications globally [13]

Core Viewpoint - The company has officially launched a strategic upgrade to create a "Global Enhanced Ethereum (ETH) Treasury" with a focus on medical innovation and asset tokenization [1][2]. Group 1: Strategic Overview - The company aims to integrate Ethereum (ETH) as a core reserve asset to enhance the efficiency of medical innovation drug development and asset allocation [3][7]. - The new "ivd.xyz" exchange will focus on high-tech assets in global medical innovation, facilitating the tokenization of real-world assets (RWA) [1][2]. Group 2: Mechanisms and Protection Strategies - The board has authorized the management to establish a "verifiable, executable, and quantifiable" seven-layer protection mechanism to safeguard shareholders and RWA holders [5]. - Additional strategies include a "three-layer enhancement engine" to transform ETH assets from passive holding to active income generation and reinvestment [5][6]. Group 3: Market Context and Trends - The strategic move aligns with global trends in cryptocurrency asset allocation, particularly among institutional investors, and responds to regulatory frameworks in regions like Hong Kong and the U.S. [4][6]. - The company has drawn insights from leading practices in the cryptocurrency asset reserve field, referencing successful models from various global firms [6][7].

Core Viewpoint - The company has signed a global strategic cooperation framework agreement with HashKey Group to enhance its digital asset services and implement its "Global Enhanced Ethereum (ETH) Treasury" strategy [1] Group 1 - The agreement aims to accelerate the implementation of the company's strategic initiatives in the digital asset space [1] - The collaboration is expected to provide more efficient, secure, and compliant digital asset services to global clients [1]

Core Viewpoint - The company has signed a global strategic cooperation framework agreement with HashKey Group to accelerate the implementation of its "Global Enhanced Ethereum (ETH) Vault" strategy and provide efficient, secure, and compliant digital asset services to global clients [1][2]. Group 1: Strategic Cooperation - The cooperation aims to leverage HashKey Group's fully licensed compliance ecosystem to provide one-stop digital asset management services, including bulk trading execution and cost optimization for Ethereum (ETH) [2][3]. - The partnership will enhance the company's ability to manage Ethereum (ETH) reserves, optimize trading costs, and access broader market resources and technical support globally [2][3]. Group 2: Ethereum (ETH) Trading Execution and Cost Optimization - HashKey Group will provide professional bulk trading execution services for Ethereum (ETH) through its compliant trading platform, ensuring transactions are executed at optimal prices and costs are further optimized through OTC services [3]. Group 3: Global Market Liquidity Support - HashKey Group's global trading platform will support the company's Ethereum (ETH) vault strategy by providing sufficient liquidity and real-time market insights to optimize investment decisions [4]. Group 4: Integration of Crypto Assets and Real Economy Assets - The collaboration will explore the integration of crypto asset reserves with real economy assets, particularly in the field of medical innovation and intellectual property tokenization, enhancing the efficiency of drug development and funding [5]. Group 5: Future Outlook - The company plans to deepen its collaboration with HashKey Group and explore innovative cooperation models to enhance its competitiveness and influence in the global Web3 space [6]. Group 6: Upcoming Event - A signing ceremony and strategic upgrade announcement event will be held on August 11, 2025, in Hong Kong, showcasing the cooperation's value and strategic blueprint [7][8].

本 公 司 董 事 會（「董事會」）欣 然 宣 佈，為 推 進 本 集 團「全 球 增 強 版 以 太 坊（ETH） 金 庫」戰 略 的 快 速 落 地，經 董 事 會 決 議 批 准，本 公 司 將 可 最 多 動 用8.8億港元於 公 開 市 場 購 買 以 太 坊（ETH）作 為 儲 備 資 產。本 公 司 將 通 過 自 有 資 金 及 透 過 募 集 資 金 活 動 籌 集 的 資 金 來 加 大 購 買 額 度，將 依 上 市 規 則 適 時 作 出 進 一 步 公 告， 包 括 但 不 限 於 召 開 股 東 大 會 通 過 加 大 購 買 額 度 等。本 公 司 已 通 過 香 港 持 牌 虛 擬資產交易所HashKey Exchange完 成 首 批 以 太 坊（ETH）的 合 規 購 買，並 計 劃 通 過 定 投 式 加 倉 策 略 持 續 增 持，目 標 成 為 港 股 市 場 乃 至 全 球 以 太 坊（ETH）儲 備 規 模 領 先 的 上 市 公 司。 截 至 本 公 告 日，本 公 司 首 批 合 共 買 入5,190枚 以 太 坊（ETH），每 枚 平 均 價 格 為 28, ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 華 檢 醫 療 致 力 於 打 造「全 球 增 強 版 以 太 坊（ETH）金 庫」，通 過 以 太 坊（ETH） 儲 備 與 創 新 藥 知 識 產 權 代 幣 化（RWA）的 雙 輪 驅 動，提 升 醫 療 創 新 藥 研 發 效 率、資 本 配 置 效 率，並 為 全 球 投 資 者 提 供 安 全、高 效 的Web3入 口。 HashKey集 團 作 為 全 球 領 先 的 數 字 資 產 金 融 服 務 集 團，在 合 規 監 管 框 架 下 構 建 了 覆 蓋 中 國 香 港、新 加 坡、日 本、百 慕 大 等 地 的 全 球 化Web3生 態，其 業 務 涵 蓋 虛 擬 資 產 交 易、數 字 資 產 管 理、合 規 場 外 交 易 及Web3基礎設施 服 務 等。 – 1 – IVD Medical Holding Limited ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1931） 自願性公告 打 造「全 球 增 強 版 以 太 坊（ETH）金 庫」、升 維 公 司 全 球 戰 略、為 生 態 參 與 者創造價值 本 公 告 由 華 檢 醫 療 控 股 有 限 公 司（「本公司」或「華檢醫療」，連 同 其 附 屬 公 司 統 稱「本集團」）董 事 會（「董事會」）自 願 作 出，旨 在 向 股 東、潛 在 投 資 者 及 市 場 各 方 全 面 闡 述 本 集 團 最 新 戰 略 升 級 暨 升 維 舉 措－經 董 事 會 決 議 通 過，本 集 團 正 式 啟 動「具 備 下 行 保 護 機 制 的 全 球 增 強 版 以 太 坊（ETH）金 庫」戰 略（「以 太 坊（ETH） 金庫戰略」） ...

Company Overview - Huajian Medical Holdings Limited was established on January 15, 2016, under the laws of the Cayman Islands, primarily engaged in investment holding [3] - The company operates three subsidiaries in Hong Kong, focusing on research, production, and sales of in vitro diagnostic medical instruments and consumables, with a workforce of over 700 employees [3] - Huajian Medical has become a leading professional company in the in vitro diagnostic industry in China, providing valuable products and services to the testing sector [3] Financial Performance - As of December 31, 2024, Huajian Medical achieved total revenue of 3.162 billion yuan, representing a year-on-year growth of 2.4% [2] - The net profit attributable to the parent company was 260 million yuan, with a year-on-year increase of 9.35% [2] - The gross profit margin stood at 23.75%, and the debt-to-asset ratio was 31.91% [2] Stock Performance - As of August 6, the stock price of Huajian Medical closed at 7.96 HKD per share, marking an increase of 38.43% with a trading volume of 8.6666 million shares and a turnover of 57.6121 million HKD [1] - Over the past month, the stock has seen a cumulative increase of 179.13%, and a year-to-date increase of 219.44%, outperforming the Hang Seng Index's growth of 24.14% [2] Valuation Metrics - Currently, there are no institutional investment ratings for Huajian Medical [3] - The company's price-to-earnings (P/E) ratio is 33.12, ranking 37th in the healthcare equipment and services industry, which has an average P/E ratio of -0.3 and a median of 1.39 [3] - Comparatively, other companies in the industry have P/E ratios such as Jingjiu Kangliao at 0.38, Juxing Medical Holdings at 0.44, and Yihui Group at 2.35 [3]